Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419163 | 1.00 | SLC29A1 (0.72) | SLC29A1TSHRPMP22ADORA3GAA | |
| SCHEMBL31307319 | 0.99 | SLC29A1 (0.73) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL31307308 | 0.96 | SLC29A1 (0.71) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL6474066 | 0.92 | SLC29A1 (0.68) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL6474053 | 0.92 | SLC29A1 (0.68) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL27570144 | 0.90 | SLC29A1 (0.58) | SLC29A1PMP22ADORA3GAAADORA2A | |
| SCHEMBL27550539 | 0.90 | SLC29A1 (0.58) | SLC29A1PMP22ADORA3GAAADORA2A | |
| SCHEMBL28409183 | 0.89 | SLC29A1 (0.67) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL31307310 | 0.88 | SLC29A1 (0.67) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL5193903 | 0.86 | ADORA1 (0.62) | ADORA3ADORA2AADORA2BADORA1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554298-A4 | PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS | ASH STEVENS INC (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1554298-A1 | PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS | ASH STEVENS, INC. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6884880-B2 | Process for the preparation of 9-β-anomeric nucleoside analogs | ASH STEVENS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| WO-2004018490-A1 | PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS | ASH STEVENS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040039190-A1 | Process for the preparation of 9-beta-anomeric nucleoside analogs | ASH STEVENS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039190-A1 | Process for the preparation of 9-beta-anomeric nucleoside analogs | DPYD, SLC29A2, GALE | SLC29A1 4/4885TSHR 4066/4885PMP22 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.